Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $108.91 USD
Change Today -1.39 / -1.26%
Volume 330.6K
AGIO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

agios pharmaceuticals inc (AGIO) Snapshot

Open
$110.44
Previous Close
$110.30
Day High
$110.78
Day Low
$106.09
52 Week High
01/15/15 - $138.85
52 Week Low
08/8/14 - $36.44
Market Cap
4.1B
Average Volume 10 Days
372.9K
EPS TTM
$-1.33
Shares Outstanding
37.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGIOS PHARMACEUTICALS INC (AGIO)

agios pharmaceuticals inc (AGIO) Related Bloomberg News

View More Bloomberg News

agios pharmaceuticals inc (AGIO) Related Businessweek News

No Related Businessweek News Found

agios pharmaceuticals inc (AGIO) Details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK deficiency. The company has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

128 Employees
Last Reported Date: 02/24/15
Founded in 2007

agios pharmaceuticals inc (AGIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $309.0K
Chief Operating Officer
Total Annual Compensation: $375.0K
Chief Medical Officer
Total Annual Compensation: $371.4K
Chief Scientific Officer
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.

agios pharmaceuticals inc (AGIO) Key Developments

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 1000 Index

Agios Pharmaceuticals, Inc. has been added to Russell 1000.

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Index

Agios Pharmaceuticals, Inc. will be removed from Russell 2000 Index

Agios Pharmaceuticals, Inc. Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Pharmaceuticals, Inc. announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of single agent AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood-brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations in cancer models. The purpose of the Phase 1 multi-center, open-label study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors. AG-881 will be administered continuously as a single agent dosed orally in a 28-day cycle. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending oral doses of AG-881 to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose based on safety and tolerability. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability and clinical activity of the recommended Phase 2 dose. Upcoming Milestones for AG-881: A second dose-escalating and expansion trial, for patients with advanced IDH1 or IDH2 mutant-positive hematologic malignancies whose cancer has progressed on a prior IDH inhibitor therapy, is expected to begin shortly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGIO:US $108.91 USD -1.39

AGIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGIO.
View Industry Companies
 

Industry Analysis

AGIO

Industry Average

Valuation AGIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.0x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGIOS PHARMACEUTICALS INC, please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.